Table 1.
Participant characteristics
| No biopsy N=2272 |
One or more negative biopsies N=221 |
Prostate cancer cases* N=85 |
|
|---|---|---|---|
| Median (range) | |||
| Age at entry | 56.0 (28.3, 88.6) | 62.0 (33.8, 82.2) | 62.8 (45.9, 80.6) |
| Race/Ethnicity | N participants (%) | ||
| Caucasian | 1213 (53.4%) | 144 (65.2%) | 50 (58.8%) |
| African American | 285 (12.5%) | 22 (10.0%) | 13 (15.3%) |
| Hispanic | 759 (33.4%) | 54 (24.4%) | 22 (25.9%) |
| Other** | 15 (0.7%) | 1 (0.5%) | 0 (0.0%) |
| First degree family members with prostate cancer | N participants (%) | ||
| No | 1866 (82.1%) | 150 (67.9%) | 54 (63.5%) |
| Yes | 406 (17.9%) | 71 (32.1%) | 31 (36.5%) |
| Number of PSA values during follow-up | N Participants (%) | ||
| 2 | 555 (24.4%) | 17 (7.7%) | 28 (32.9%) |
| 3 | 469 (20.6%) | 33 (14.9%) | 27 (31.8%) |
| 4 | 345 (15.2%) | 25 (11.3%) | 22 (25.9%) |
| 5 | 312 (13.7%) | 44 (19.9%) | 8 (9.4%) |
| ≥ 6 | 591 (26.0%) | 102 (46.2%) | 0 (0.0%) |
| Number of abnormal DREs during follow-up | N participants (%) | ||
| 0 abnormal | 1895 (83.4%) | 114 (51.6%) | 58 (68.2%) |
| 1 | 145 (6.4%) | 40 (18.1%) | 15 (17.6%) |
| ≥ 2 | 41 (1.8%) | 36 (16.3%) | 5 (5.9%) |
| Not performed or result unknown | 191 (8.4%) | 31 (14.0%) | 7 (8.2%) |
| Number of PSAs ≥ 2.5 ng/mL during follow-up | N participants (%) | ||
| 0 | 1806 (79.5%) | 94 (42.5%) | 29 (34.1%) |
| 1 | 195 (8.6%) | 29 (13.1%) | 18 (21.2%) |
| 2 | 107 (4.7%) | 17 (7.7%) | 19 (22.4%) |
| 3 | 67 (2.9%) | 28 (12.7%) | 13 (25.3%) |
| 4 | 43 (1.9%) | 15 (6.8%) | 4 (4.7%) |
| 5 | 31 (1.4%) | 10 (4.5%) | 2 (2.4%) |
| ≥ 6 | 23 (1.0%) | 28 (12.7%) | 0 (0.0%) |
*
6 prostate cancer cases had one prior negative biopsy, 3 had two prior negative biopsies
**
American Indian, Asian or Hawaiian/pacific islander